PARP — Drug Target

All drugs that target PARP — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

PARP inhibitor

Phase 3 pipeline (1)

• ddAC-CP-Olaparib · The Netherlands Cancer Institute · PARP inhibitor · Oncology
  ddAC-CP-Olaparib is a PARP inhibitor that works by blocking the enzyme PARP, which is involved in DNA repair.

Phase 2 pipeline (3)

• ABT-888 · AbbVie (prior sponsor, Abbott) · PARP inhibitor · Oncology
  ABT-888 is a PARP inhibitor that works by blocking the action of poly (ADP-ribose) polymerase (PARP) enzymes.
• AZD2281 · AstraZeneca · PARP inhibitor · Oncology
  PARP inhibitor
• AZD6738 and olaparib · AstraZeneca · PARP inhibitor · Oncology
  PARP inhibitor